This is a signal that CNTGF's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options. A.I.dvisor identified 66 similar cases where CNTGF's stochastic oscillator exited the oversold zone, and of them led to successful outcomes. Odds of Success:
CNTGF saw its Momentum Indicator move above the 0 level on October 31, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 108 similar instances where the indicator turned positive. In of the 108 cases, the stock moved higher in the following days. The odds of a move higher are at .
CNTGF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 138 cases where CNTGF Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (12.507). P/E Ratio (0.000) is within average values for comparable stocks, (139.301). CNTGF's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.955). CNTGF has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.016). P/S Ratio (0.053) is also within normal values, averaging (9.843).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CNTGF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CNTGF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
a commercial-stage company, which focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies
Industry MedicalSpecialties